By Matthew Perlman ( May 13, 2016, 6:16 PM EDT) -- Mylan NV and Novartis AG are among possible suitors exploring a purchase of Teva Pharmaceutical Industries Ltd.'s portfolio of drugs in the U.K., Ireland and Iceland, a Bloomberg report said Friday. Teva could bring in as much as $2 billion for the businesses, which are also seeing interest from private equity investors Apollo Global Management LLC and Cinven Ltd., according to the report. The company is working with Greenhill & Co. to find a buyer, in order to win regulatory approval for its planned $40.5 billion acquisition of Allergan PLC's generics business, the report said....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.